We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fifth-Generation Cardiac Troponin Assays Compared

By LabMedica International staff writers
Posted on 20 Aug 2018
Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are highly specific biomarkers of myocardial injury. More...
The 99th percentile upper reference limit (URL) of a normal reference population is the recommended threshold which defines an increased cTnI or cTnT plasma concentration indicative for myocardial injury.

In Europe, physicians have been using the so-called high-sensitivity cTnI (hs-cTnI) and high-sensitivity cTnT (hs-cTnT) assays for several years in clinical routine. These high-sensitivity assays, which are more analytically sensitive than former assays for the measurement of cardiac troponins, are also termed 5th generation assays.

Medical laboratory scientists at the Konventhospital Barmherzige Brueder Linz (Linz, Austria) studied 3,588 consecutive patients presenting to an emergency department. In a retrospective study they measured hs-cTnT plasma concentrations with the 5th generation “Troponin T hs” assay on a modular platform in clinical routine since January 2010.

Due to a changeover of their analytical systems, they switched to the 5th generation “STAT High Sensitive Troponin-I" assay by using an ARCH-ITECT i2000SR analyzer for clinical routine use in our hospitals since February 2013. The team assessed the capabilities of hs-cTnI and hs-cTnT for the prediction of 3.7 year all-cause mortality; discordant diagnoses of myocardial injury by hs-cTnI and hs-cTnT according to the European gender-neutral 99th percentile upper reference limits (i.e., 26 ng/L and 14 ng/L, respectively); and (3) analyte kinetics in patient with serial troponin measurements.

The scientists reported that with respect to prognosis of all-cause mortality, the AUC of hs-cTnI was 0.81 (95% CI, 0.80–0.82), and the AUC of hs-cTnT was 0.85 (95% CI, 0.84–0.86). With respect to discordant diagnoses, 21% of the 3,588 patients were classified as having myocardial injury by hs-cTnT but not by hs-cTnI, and less than 1% were classified as having myocardial injury by hs-cTnI but not by hs-cTnT. In the patients with serial blood sampling, the median delta values were 6.3 ng/L and 25% for hs-cTnI, and 4.2 ng/L and 16% for hs-cTnT.

The authors concluded that they had found different characteristics of the Abbott hs-cTnI and the Roche hs-cTnT assays, especially when using the European gender-neutral 99th percentile upper reference limits. Clinically, these different characteristics are related to discordant results in the diagnosis and prognosis of patients presenting to an emergency department. The study has been available online since June 27, 2018, in the journal Clinica Chimica Acta.

Related Links:
Konventhospital Barmherzige Brueder Linz


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.